Kailera Therapeutics News and Activities

Kailera Therapeutics is one of the...

• TOB Iconic 10,000;
• Unicorn.

Acquisition, funding and merger involving Kailera Therapeutics.

• Kailera Therapeutics has just announced a $625 Million fundraising (posted on April 17 2026).
• Kailera Therapeutics is now listed under ticker KLRA. (posted on April 17 2026).
• Kailera Therapeutics has just announced a $600 Million fundraising (posted on October 21 2025).
• Kailera Therapeutics has just announced a $400 Million fundraising (posted on October 4 2024).
• See more news about Kailera Therapeutics Hide news involving Kailera Therapeutics

View the org chart displaying its 30 main executives

Most searched biographies at Kailera Therapeutics

• Ron Renaud, President and Chief Executive Officer
• Martin Mackay, Director
• Yuting Liu, Director

Popular executive movements at Kailera Therapeutics

• Doug Pagan has joined the company as Chief Financial Officer  (posted on January 6 2026).
• Laurie Stelzer, Chief Financial Officer, has left the company  (posted on November 4 2025).
• Frank Clyburn has joined the company as Director  (posted on November 4 2025).

Create your alert
to follow the executive moves at Kailera Therapeutics.

Kailera Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Kailera Therapeutics

• Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference | Thu, 05/28/2026 - 16:05
• Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | Tue, 05/26/2026 - 16:02
• Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions | Wed, 05/13/2026 - 07:30
• Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Mon, 04/20/2026 - 16:06
• Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide - Kailera
• Kailera | GLP-1 Therapies for Obesity Care | Press Releases
• Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531) - Kailera
• Kailera Therapeutics Appoints Doug Pagán as Chief Financial Officer - Kailera
• Kailera Therapeutics to Participate in Upcoming November Investor Conferences - Kailera
• Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 - Kailera
• View more press releases Close

Social media about Kailera Therapeutics

• Kailera Therapeutics on Wikipedia, Google News & Yahoo Finance
• Kailera Therapeutics on LinkedIn, X (Twitter) & YouTube